Harpoon Therapeutics appoints James Bucher as CLO, Wendy Chang as CPO

Harpoon Therapeutics (HARP) announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the CEO. Most recently, Bucher served as Executive Vice President, General Counsel, and Head of Human Resources at Eliem Therapeutics (ELYM). Chang joined Harpoon in 2022 as Senior Vice President of Human Resources. In connection with Mr. Bucher’s appointment, Harpoon Therapeutics granted him an inducement non-qualified stock option to purchase an aggregate of 110,000 shares of Harpoon’s common stock. The stock option grant has an exercise price per share equal to $11.30, Harpoon’s closing trading price on Nasdaq on the grant date of December 21, 2023, and will vest over 4 years, with 1/4 of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months, subject to Mr. Bucher’s continued service relationship with Harpoon through the applicable vesting dates.